China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
S&P 500 Hits Record High as Soft Inflation Data Eases Fed Rate Hike Fears 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Canada-US Trade Talks Gain Momentum Ahead of Aug. 19 Tariff Deadline 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
US Dollar Holds Firm as Fed Outlook and Iran Tensions Keep Markets on Edge 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
Gold Prices Slip From Two-Month High as Inflation and Fed Outlook Drive Markets 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Asian Currencies Steady as Dollar Holds Firm After U.S. Inflation Data 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
US Dollar Slips as Weak Retail Sales Reduce Fed Rate Hike Bets 
European Stocks Steady as U.S.-Iran War, Euro Zone Data Keep Investors Cautious 
Asian Stocks Rally as Cooling US Inflation Boosts Fed Rate Outlook 
US Dollar Slips as Softer PPI Data Eases Fed Rate Hike Expectations 
Add as a preferred source on Google
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
